Lung Cancer Clinical Trial

Use Peripheral Blood Proteomics to Predict the Treatment Response and Toxicities in NSCLC Immunotherapy

Summary

Peripheral blood contains enormous quantity of biological information that can improve our patient care. Investigators plan to use proteomics from serum to study its value in predicting the therapeutic response and toxicities of immunotherapy in non-small cell lung cancer (NSCLC).

View Full Description

Full Description

An extra tube of blood for research will be collected from consented subjects prior to the initiation of anti-PD-1/L1 based immunotherapy, either single agent or in combination with chemotherapy. The blood will be coded, processed and sent for analysis. Results of analysis will be correlated with clinical data to see whether serum proteomics can be a good therapeutic predictor for future studies and treatments of NSCLC.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Non Small Cell Lung Cancer (NSCLC) patients who were previously untreated receiving anti-PD1 or anti-PD-L1 therapies, either single agent or in combination with chemotherapy.
NSCLC patients who were treated with one previous line of therapy (not containing IO) and now receiving anti-PD1 or anti-PD-L1 therapies, either single agent or in combination with chemotherapy.

Exclusion Criteria:

Patients not capable of making medical decisions
Any patients who do not meet the inclusion criteria

Study is for people with:

Lung Cancer

Estimated Enrollment:

100

Study ID:

NCT03951012

Recruitment Status:

Recruiting

Sponsor:

Taher Abu Hejleh

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

University of Iowa Hospitals and Clinics
Iowa City Iowa, 52242, United States More Info
Taher Abu Hejleh, MBBS
Contact
319-384-9502
[email protected]

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Estimated Enrollment:

100

Study ID:

NCT03951012

Recruitment Status:

Recruiting

Sponsor:


Taher Abu Hejleh

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider